MITSUI-CHEMICALS
VECTRONTM T500 is a new IRS product containing TENEBENALTM, the world’s first meta-diamide active ingredient (IRAC Group 30) developed by Mitsui Chemicals Agro which has a different mode of action from existing vector control products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005328/en/
Mosquitoes in Bugesera district, Rwanda. Photographed by Mitsui Chemicals Agro.
VECTRONTM T500 will support the rotation of insecticides in line with best practice insecticide resistance management, which is critical to preserve the long-term efficacy of vector control tools. VECTRONTM T500 has outstanding efficacy against malaria vector mosquitoes including strains and populations resistant to pyrethroids and some other insecticides. It works on a variety of types of wall surfaces, including mud, and shows long residual efficacy.
VECTRONTM T500 is non-repellent, odorless and stainless formulation with low mammalian acute toxicity, and is supplied in easy-to-handle 50g aluminum sachets.
Mitsui Chemicals Agro will launch VECTRONTM T500 in sub-Saharan African countries from 2023 in line with locally required conditions of use.
OZAWA says: “Mitsui Chemicals Agro is an R&D driven chemical company, that has been developing malaria vector control products to save human lives. Our mission is to provide solutions to health challenges through the development and deployment of innovative, high-quality products. We are committed to malaria eradication and are excited about the launch of VECTRONTM T500. We appreciate the support of all our stakeholders and partners in reaching this important milestone.”
Justin McBeath CEO of IVCC added: “IVCC was established with a mission to work with partners, such as Mitsui Chemicals Agro, to accelerate the availability of new public health insecticides which will help address the significant threat of insecticide resistance in malaria vectors. We are delighted to have supported Mitsui Chemicals Agro on their achievement of the PQ-listing of this important breakthrough product which represents another significant milestone in the fight against malaria.”
Notes to Editors
Mitsui Chemicals Agro, Inc.
Mitsui Chemicals Agro is an R&D driven company that is a global provider of solutions by high-quality products and services in the agrochemicals field. The company has a history of about 100 years beginning with the manufacture and release of the first synthetic agrochemical in Japan. Mitsui Chemicals Agro has been contributing human health and comfortable life through PPM (Professional Pest Management) business, providing unique active ingredients and formulated products. Mitsui Chemicals Agro is 100% subsidiary of Mitsui Chemicals (Tokyo:4183, ISIN: JP3888300005) which has an annual sale of 1,612 billion yen in the fiscal year ending March 2022.
IVCC
IVCC is the only Product Development Partnership (PDP) working in vector control. IVCC was established in 2005, through an initial $50 million grant to the Liverpool School of Tropical Medicine (LSTM) from the Bill & Melinda Gates Foundation and has since provided ongoing support for IVCC activities. As a registered charity in the UK, IVCC is also funded by UK Aid, USAID and the Swiss Agency for Development and Cooperation to work with stakeholders to facilitate the development of novel and improved public health insecticides and formulations to combat the rapidly growing problem of insecticide resistance. In addition, IVCC is also funded by Unitaid and the Global Fund to implement catalytic market access projects, such as NgenIRS and the New Nets Project which support the rapid and scaled deployment of innovative vector control interventions. IVCC brings together partners from industry, the public sector and academia to create new solutions to prevent disease transmission. By focusing resources and targeting practical scientific solutions we accelerate the process from innovation to impact.
Reference
*1) WHO -Prequalification of Vector Control Products- VECTRONTM T500
https://extranet.who.int/pqweb/vector-control-product/vectron-t500
- VECTRONTM T500: https://www.vectront500.com/
- Mitsui Chemicals Agro, Inc.: https://www.mitsui-agro.com/en/
- IVCC: https://www.ivcc.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005328/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
L&T Technology Services, PALFINGER Inaugurate GDC as Part of Multi-Year Engagement to Accelerate Product Development10.12.2025 08:30:00 CET | Press release
The GDC, established in LTTS’ Mobility segment, will strengthen PALFINGER’s localization roadmap and next-gen digital transformation initiatives L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced the inauguration of a state-of-the-art Global Development Center - APAC as part of a multi-year engagement with PALFINGER, an Austria-headquartered global pioneer in innovative crane and lifting solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209416315/en/ From PALFINGER, the ceremony was attended by Alexander Susanek (COO), Andreas Hille (Senior Vice President, Product Line Management and Engineering), Santhosh Rao (Senior Vice President Regional Sales & Service, Asia Pacific) and Arun C Bhongale (General Manager, SCM and Procurement). From LTTS, Mritunjay Singh (COO), Dr. Oliver Moron (Vice President, EU-DACH), Mohideen Farouk (Sales Director, E
New Study Reveals Surging Consumer Demand for Seamless Car-to-Home Audio10.12.2025 08:10:00 CET | Press release
Cinemo and Futuresource Consulting’s research indicates consumer readiness for integrated audio environments, accelerating the shift from connected devices to a connected lifestyle. Over 9 in 10 consumers say they are likely to seek out audio devices that allow smooth movement between car and home, according to a consumer survey conducted by Futuresource Consulting on behalf of Cinemo, a leading provider of in-car infotainment solutions and the company behind the first open cloud ecosystem connecting audio devices, content, and users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209006640/en/ "From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience" Survey conducted by Futuresource Consulting on behalf of Cinemo; November 2025 The report, “From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience”, drawn from more than 500 connected device users in China, where
Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases10.12.2025 07:01:00 CET | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market. Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar. Libbs Farmacêutica will hold an exclusive license for the commercialization, marketing and distribution of the biosimilar in Brazil. This collaboration opens up exciting new opportunities and demonstrates the shared commitment of both companies to delivering innovative and accessible therapies to patients. “Entering the Brazilian market with a biosimilar is a significant step for Polpharma Biologics and reflects our ongoing mission to expand access to high-qual
NayaPay Launches Global QR Payments for Pakistanis via Alipay+10.12.2025 05:00:00 CET | Press release
NayaPay, one of Pakistan’s fastest growing fintech platforms, has launched global QR payments in collaboration with Alipay+, Ant International’s global wallet gateway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209591389/en/ The partnership enables millions of NayaPay users to scan-and-pay at Alipay+ merchants initially across more than 50 countries, connecting Pakistani consumers to an extensive global ecosystem spanning retail, dining, transport, healthcare, entertainment and more. With this innovative feature, paying abroad just got faster and more affordable. With NayaPay, Pakistanis can now scan and pay securely worldwide with lower costs, less friction, and a seamless checkout experience wherever they go. Alipay+ connects 40 international mobile payment partners to more than 150 million merchants globally. The launch reinforces NayaPay’s commitment to delivering world-class payment experiences to Pakistani consu
Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator10.12.2025 03:50:00 CET | Press release
Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209977992/en/ The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen’s market capitalization exceeds 25.9 billion RMB. Biocytogen’s proprietary RenMice® platforms (RenMab™, RenLite®, RenNano®, RenTCR-mimic™) enable the discovery of fully hum
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
